Nucleoside transport in L1210 murine leukemia cells. Evidence for three transporters. 1990

C R Crawford, and C Y Ng, and L D Noel, and J A Belt
Department of Biochemical and Clinical Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38101.

L1210 murine leukemia cells have two nucleoside transport activities that differ in their sensitivity to nitrobenzylmercaptopurine riboside (NBMPR). This study re-examines NBMPR-insensitive nucleoside transport in these cells and finds that it is mediated by two components, one Na(+)-dependent and the other Na(+)-independent. A mutant selected previously for loss of NBMPR-insensitive transport lacks only the Na(+)-independent activity. When NBMPR is used to block efflux via the NBMPR-sensitive transporter, uptake of formycin B (a nonmetabolized analog of inosine) is concentrative in both the parental and mutant cells, but the intracellular concentration of the nucleoside is 5-fold lower in the parental cells. Decreased accumulation of formycin B in the parental cells is due to efflux of the nucleoside via the NBMPR-insensitive, Na(+)-independent transporter that the mutant lacks. The Na(+)-dependent transporter appears to accept most purine, but not pyrimidine, nucleosides as substrates. Two exceptions are uridine, a good substrate, and 7-deazaadenosine, a poor substrate. In contrast, all of the nucleosides tested are substrates for the Na(+)-independent transporter. We conclude that L1210 cells have three distinct nucleoside transporters and that the specificity of the Na(+)-dependent transporter is similar to that of one of the two Na(+)-dependent nucleoside transporters seen in mouse intestinal epithelial cells.

UI MeSH Term Description Entries
D007288 Inosine A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. (Dorland, 28th ed)
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D009705 Nucleosides Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed) Nucleoside,Nucleoside Analog,Nucleoside Analogs,Analog, Nucleoside,Analogs, Nucleoside
D005573 Formycins Pyrazolopyrimidine ribonucleosides isolated from Nocardia interforma. They are antineoplastic antibiotics with cytostatic properties.
D000345 Affinity Labels Analogs of those substrates or compounds which bind naturally at the active sites of proteins, enzymes, antibodies, steroids, or physiological receptors. These analogs form a stable covalent bond at the binding site, thereby acting as inhibitors of the proteins or steroids. Affinity Labeling Reagents,Labeling Reagents, Affinity,Labels, Affinity,Reagents, Affinity Labeling
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D001692 Biological Transport The movement of materials (including biochemical substances and drugs) through a biological system at the cellular level. The transport can be across cell membranes and epithelial layers. It also can occur within intracellular compartments and extracellular compartments. Transport, Biological,Biologic Transport,Transport, Biologic
D013868 Thioinosine Sulfhydryl analog of INOSINE that inhibits nucleoside transport across erythrocyte plasma membranes, and has immunosuppressive properties. It has been used similarly to MERCAPTOPURINE in the treatment of leukemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p503) 6-Mercaptopurine Riboside,NSC-4911,Ribosyl-6-mercaptopurine,6 Mercaptopurine Riboside,Riboside, 6-Mercaptopurine,Ribosyl 6 mercaptopurine

Related Publications

C R Crawford, and C Y Ng, and L D Noel, and J A Belt
January 1978, The Journal of biological chemistry,
C R Crawford, and C Y Ng, and L D Noel, and J A Belt
April 1991, The Journal of biological chemistry,
C R Crawford, and C Y Ng, and L D Noel, and J A Belt
June 1981, Research communications in chemical pathology and pharmacology,
C R Crawford, and C Y Ng, and L D Noel, and J A Belt
September 1988, The Journal of biological chemistry,
C R Crawford, and C Y Ng, and L D Noel, and J A Belt
December 1990, Pharmaceutical research,
C R Crawford, and C Y Ng, and L D Noel, and J A Belt
January 1988, The Biochemical journal,
C R Crawford, and C Y Ng, and L D Noel, and J A Belt
January 1978, Biokhimiia (Moscow, Russia),
C R Crawford, and C Y Ng, and L D Noel, and J A Belt
December 1993, Cancer research,
C R Crawford, and C Y Ng, and L D Noel, and J A Belt
January 1992, Oncology research,
C R Crawford, and C Y Ng, and L D Noel, and J A Belt
April 1981, Cancer research,
Copied contents to your clipboard!